Bad times for the scandal surgeon Paolo Macchiarini and his acolyte Philipp Jungebluth. Misconduct findings led previously to retraction of an oesophagus transplant paper, with more soon to be expected, their employments in academia seem to be definitely a thing of a past. Macchiarini’s big plans of world-shattering trachea and oesophagus transplants in Russia went bust, when his grant funding was not extended and the Federal University of Kazan waved him goodbye. The master’s acolyte Jungebluth is currently suing me in court about my reporting on his own past employment, because he managed to convince the Berlin judge when passing the injunction that all his now proven research misconduct and patient abuse, which led to deaths of several patients, plus several other dishonest deeds of his, had in fact perfectly qualified him for an academic research career at the University of Heidelberg in Germany. A career he claims to have aborted entirely on his own accord, hence his (now only 1/3 successful) court injunction against me. Jungebluth, after having said farewell to his 8 years of thorax surgery training in vain, even claimed in court to be desperately wanted as thoracic surgeon by all Berlin hospitals, including the huge university hospital Charité.
Which brings us to the recent setback for the two trachea transplanters. Their publications regarding the plastic trachea operations at the Karolinska Institutet (KI) in Stockholm, which left three patients dead, were investigated by two external experts. One of the experts was Martin Björck, professor of surgery at University of Uppsala, the other was Detlev Ganten, professor emeritus of pharmacology and former CEO of the Charité. And their fresh report, submitted to the Swedish Central Ethics Review Board (CEPN), does not read like the Berlin Charité or any other medical research institution in Germany, or anywhere else for that matter, might ever consider employing Jungebluth. The central Lancet publication, describing the first plastic trachea transplant performed on Andemariam Beyene (Jungebluth et al, 2011), was slammed as based on misconduct, both ethical as well as research misconduct. It is the same Lancet paper Jungebluth presented to Berlin court as evidence of his scientific fame and excellence.